A. Bosma

发表

Reply to "Comment on 'Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry'".

M. Hof, P. Spuls, D. Hijnen, 2021, Journal of the American Academy of Dermatology.

Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.

M. Hof, P. Spuls, D. Hijnen, 2020, Journal of the American Academy of Dermatology.

Learning from disease registries during a pandemic: Moving toward an international federation of patient registries

S. Feldman, E. Freeman, C. Flohr, 2021, Clinics in Dermatology.

Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics

K. Abuabara, P. Spuls, A. Mulick, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries

C. Flohr, J. Schmitt, A. Manca, 2019, The British journal of dermatology.

TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema

L. Naldi, C. Flohr, J. Schmitt, 2019, The British journal of dermatology.

Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

P. van Paassen, A. ten Brinke, G. D'Haens, 2022, Annals of the Rheumatic Diseases.

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

S. Nejentsev, C. Allaart, W. Lems, 2022, The Lancet Rheumatology.

The effects of systemic immunomodulatory treatments on COVID‐19 outcomes in patients with atopic dermatitis: results from the global SECURE‐AD registry

E. Freeman, C. Flohr, E. Haufe, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

R. R. Hagen, S. Nejentsev, P. van Paassen, 2022, The Lancet Rheumatology.

Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types

C. Flohr, G. Ogg, P. Beattie, 2022, JAAD international.

Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series

P. Spuls, A. Bosma, L. Gerbens, 2021, Clinical and experimental dermatology.

Effectiveness of a skin care programme for the prevention of contact dermatitis in healthcare workers (the Healthy Hands Project): A single‐centre, cluster randomized controlled trial

J. Sluiter, S. Kežić, T. Rustemeyer, 2019, Contact dermatitis.

Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

P. van Paassen, F. Bemelman, G. D'Haens, 2023, Journal of Autoimmunity.

Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data

T. Nijsten, N. Erler, P. Spuls, 2019, The British journal of dermatology.

Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

P. van Paassen, A. ten Brinke, F. Bemelman, 2023, BMC Infectious Diseases.

Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic

C. Flohr, P. Di Meglio, N. Dand, 2020, The British journal of dermatology.

Work ability and quality of working life in atopic dermatitis patients treated with dupilumab

A. D. de Boer, B. Arents, P. Spuls, 2021, The Journal of dermatology.

Children with atopic eczema experiencing increased disease severity in the pollen season more often have hay fever at a young age and a dark skin type

W. Ouwerkerk, A. Bosma, M. Middelkamp-Hup, 2021, The Journal of dermatology.

The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study.

P. Spuls, T. Rispens, A. Bosma, 2023, The Journal of dermatological treatment.

The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) glossary: developing a lingua franca to facilitate data harmonization and cross‐cohort analyses

C. Flohr, V. Satagopam, J. Min, 2021, The British journal of dermatology.

[Abdominal telangiectasias in a newborn].

A. Bosma, Dave Van der Zwaan, 2022, Nederlands tijdschrift voor geneeskunde.

Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce

C. Flohr, E. Haufe, J. Schmitt, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

The selection process for a web-based application to measure patient-reported outcomes following the example of the TREAT NL registry.

Ronald Cornet, Rowdy de Groot, Angela L Bosma, 2020, The Journal of investigative dermatology.

Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

C. Allaart, P. van Paassen, A. ten Brinke, 2022, BMC Medicine.

TREatment of ATopic eczema (TREAT) Registry Taskforce: method for comparing the safety of dupilumab with other systemic therapies for moderate‐to‐severe eczema

L. Naldi, C. Flohr, J. Schmitt, 2020 .

Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic

N. Dand, F. Capon, S. Mahil, 2020, The British journal of dermatology.

Real‐world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

W. Ouwerkerk, A. Bosma, A. Musters, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.